李新明,王天松,刘中民,王圣,李斌,陈关良,王青

• 1: 上海市东方医院心内科中德心脏中心
• 2:上海市东方医院心内科中德心脏中心
• 3:上海市东方医院心内科中德心脏中心
• 4:上海市东方医院心内科中德心脏中心

摘要(Abstract)：

目的比较药物洗脱支架与冠状动脉旁路移植术治疗冠状动脉复杂多支病变的疗效。方法连续入选行血运重建治疗的冠心病多支病变患者200名,随机分为经皮冠状动脉介入(PCI)组和冠状动脉旁路移植术(CABG)组,每组100例。PCI组和CABG组中分别有合并糖尿病者(糖尿病亚组)27例和25例。观察术后1年内主要心脑血管不良事件(死亡、脑卒中、非致死性心肌梗死、靶血管再次血运重建)、再狭窄、心绞痛复发发生率,血浆肌酸激酶水平和PCI组支架内血栓形成发生率。结果两组患者的基线特征差异无统计学意义。PCI组与CABG组1个月、6个月和1年的主要心脑血管不良事件发生率分别为4.0%、7.0%、12.0%比6.0%、9.0%、15.2%(P>0.05);心绞痛复发率分别为2.0%、4.0%、6.0%比1.0%、3.0%、5.1%(P>0.05)。术后1年再狭窄率分别为11.3%比13.2%(P>0.05)。PCI组术后亚急性血栓形成率1.0%。PCI组和CABG组术后肌酸激酶MB型同工酶升高的患者比例分别为26%比82%(P<0.05)。PCI组糖尿病亚组与CABG组糖尿病亚组1个月、6个月和1年的严重心脑血管不良事件发生率分别为7.4%、11.1%、18.5%比8.0%、16.0%、24.0%(P>0.05)。结论药物洗脱支架时代PCI与CABG治疗冠状动脉多支病变的近、远期疗效相近,对于合并糖尿病的患者同样有效。

关键词(KeyWords)： 支架;冠状动脉旁路移植术;冠状动脉疾病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李新明,王天松,刘中民,王圣,李斌,陈关良,王青

参考文献(References)：

• [1]Aoki J,Ong AT,Arampatzis CA,et al.Comparison of three-year outcomes after coronary stenting versus coronary artery by-pass grafting in patients with multivessel coronary disease,inclu-ding involvement of the left anterior descending coronary artery proximally(a subanalysis of the arterial revascularization thera-pies study trial).Am J Cardiol,2004,94:627-631.
• [2]SoS Investigators.Coronary artery bypass surgery versus percuta-neous coronary intervention with stent implantation in patients with multivessel coronary artery disease(the Stent or Surgery tri-al):a randomized controlled trial.Lancet,2002,360:965-970.
• [3]Rodriguez A,Rodraguez AM,Baldi J,et al.Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis:results from the ERACI II study.Heart,2003,89:184-188.
• [4]Hueb W,Soares PR,Gersh BJ,et al.The medicine,angioplas-ty,or surgery study(MASS-II):a randomized,controlled clini-cal trial of three therapeutic strategies for multivessel coronary ar-tery disease:one-year results.J Am Coll Cardiol,2004,43:1743-1751.
• [5]Regar E,Serruys PW,Bode C,et al.Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent(RAVEL):sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.Circula-tion,2002,106:1949-1956.
• [6]Holmes DR Jr,Leon MB,Moses JW,et al.Analysis of1-year clinical outcomes in the SIRIUS trial:a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.Circulation,2004,109:634-640.
• [7]Schluter M,Schofer J,Gershlick AH,et al.Direct stenting of n-ative de novo coronary artery lesions with the sirolimus-eluting stent:a post hoc subanalysis of the pooled E-and C-SIRIUS tri-als.J Am Coll Cardiol,2005,45:10-13.
• [8]Serruys PW.Arterial revascularization therapies study part of the sirolimus-eluting stent in the treatment of patients with multives-sel de novo coronary artery lesions.J Am Coll Cardio,2005,45:1056-1058.
• [9]Iakovou I,Schmidt T,Bonizzoni E,et al.Incidence,predic-tors,and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA,2005,293:2126-2130.
• [10]Serruys PW,Unger F,Sousa JE,et al.Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.N Engl J Med,2001,344:1117-1124.
• [11]Bernstein SJ,Rigter H,Brorsson B,et al.Waiting for coronary revascularization:a comparison between New York State,the Netherlands and Sweden.Health Policy,1997,42:15-27.
• [12]Teo KK,Spoor M,Pressey T,et al.Impact of managed waiting for coronary artery bypass graft surgery on patients'perceived quality of life.Circulation,1998,98:II29-1133.
• [13]Jackson NW,Doogue MP,Elliott JM.Priority points and cardiac events while waiting for coronary bypass surgery.Heart,1999,81:367-373.
• [14]Califf RM,Abdelmeguid AE,Kuntz RE,et al.Myonecrosis af-ter revascularization procedures.J Am Coll Cardiol,1998,31:241-251.
• [15]Costa MA,Carere RG,Lichtenstein SV,et al.Incidence,pre-dictors,and significance of abnormal cardiac enzyme rise in pa-tients treated with bypass surgery in the arterial revascularization therapies study(ARTS).Circulation,2001,104:2689-2693.
• [16]Sabate M,Jimenez-Quevedo P,Angiolillo DJ,et al.Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients:the diabetes and sirolimus-eluting stent(DIABETES)trial.Circula-tion,2005,112:2175-2183.